NZ510528A - 2, 4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors - Google Patents
2, 4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptorsInfo
- Publication number
- NZ510528A NZ510528A NZ510528A NZ51052899A NZ510528A NZ 510528 A NZ510528 A NZ 510528A NZ 510528 A NZ510528 A NZ 510528A NZ 51052899 A NZ51052899 A NZ 51052899A NZ 510528 A NZ510528 A NZ 510528A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carbons
- alkyl
- group
- formula
- phenyl
- Prior art date
Links
- SDVVLIIVFBKBMG-ONEGZZNKSA-N (E)-penta-2,4-dienoic acid Chemical class OC(=O)\C=C\C=C SDVVLIIVFBKBMG-ONEGZZNKSA-N 0.000 title 1
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- -1 5 or 6 membered heteroaryl radical Chemical class 0.000 abstract 3
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 abstract 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/164,950 US6147224A (en) | 1998-10-01 | 1998-10-01 | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| PCT/US1999/021712 WO2000020370A1 (en) | 1998-10-01 | 1999-09-20 | 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ510528A true NZ510528A (en) | 2003-04-29 |
Family
ID=22596791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ510528A NZ510528A (en) | 1998-10-01 | 1999-09-20 | 2, 4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6147224A (enExample) |
| EP (2) | EP1388534A3 (enExample) |
| JP (1) | JP2002526516A (enExample) |
| KR (2) | KR20010075457A (enExample) |
| CN (1) | CN1328538A (enExample) |
| AR (1) | AR020691A1 (enExample) |
| AT (1) | ATE254593T1 (enExample) |
| AU (1) | AU757932B2 (enExample) |
| BR (1) | BR9914256A (enExample) |
| CA (1) | CA2346034A1 (enExample) |
| DE (1) | DE69912973T2 (enExample) |
| ES (1) | ES2207339T3 (enExample) |
| NZ (1) | NZ510528A (enExample) |
| TW (1) | TW580494B (enExample) |
| WO (1) | WO2000020370A1 (enExample) |
| ZA (1) | ZA200102635B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667313B1 (en) | 1999-08-27 | 2003-12-23 | Ligand Pharmaceuticals Inc. | 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators |
| DE60027443D1 (de) | 1999-08-27 | 2006-05-24 | Ligand Pharm Inc | Androgenrezeptor-modulatorverbindungen und verfahren |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| CO5200852A1 (es) * | 1999-09-14 | 2002-09-27 | Lilly Co Eli | Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides |
| US6906046B2 (en) | 2000-12-22 | 2005-06-14 | Celltech R & D Inc. | Pharmaceutical uses and synthesis of benzobicyclooctanes |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| WO2002076941A2 (en) * | 2001-03-27 | 2002-10-03 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US6388105B1 (en) * | 2001-09-27 | 2002-05-14 | Allergan Sales, Inc. | Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| CA2486303C (en) | 2002-05-22 | 2013-04-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| EP1567142A4 (en) | 2002-11-20 | 2005-12-14 | Errant Gene Therapeutics Llc | TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS |
| US6683092B1 (en) | 2003-04-09 | 2004-01-27 | Allergan, Inc. | [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity |
| US6734193B1 (en) | 2003-06-03 | 2004-05-11 | Allergan, Inc. | (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity |
| US6936636B2 (en) * | 2003-06-26 | 2005-08-30 | Allergan, Inc. | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
| US6887896B1 (en) | 2003-10-29 | 2005-05-03 | Allergan, Inc. | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity |
| CA2623638A1 (en) | 2005-09-30 | 2007-04-12 | Vitae Pharmaceuticals, Inc. | Treatment of cancer with specific rxr agonists |
| US20070185055A1 (en) * | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
| AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| CN105308026B (zh) * | 2013-07-09 | 2018-12-21 | 东曹株式会社 | 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件 |
| KR102489706B1 (ko) | 2015-10-31 | 2023-01-17 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
| EP3426303B1 (en) | 2016-03-10 | 2022-06-15 | IO Therapeutics, Inc. | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| MX386643B (es) | 2016-03-10 | 2025-03-19 | Io Therapeutics Inc | Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas. |
| US11517549B2 (en) | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
| CA3082485A1 (en) * | 2017-11-17 | 2019-05-23 | Io Therapeutics, Inc. | Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| KR20240119103A (ko) | 2021-12-07 | 2024-08-06 | 아이오 테라퓨틱스, 인크. | Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도 |
| KR20240115316A (ko) | 2021-12-07 | 2024-07-25 | 아이오 테라퓨틱스, 인크. | 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8826760D0 (en) * | 1988-11-16 | 1988-12-21 | Wellcome Found | Pesticides |
| EP0807624B1 (en) * | 1991-12-18 | 2009-08-12 | The Salk Institute For Biological Studies | Retinoic acid derivatives |
| DK0637297T3 (da) * | 1992-04-22 | 2000-09-18 | Ligand Pharm Inc | Forbindelser, der har selektivitet til retinoid-X-receptorer |
| WO1995004036A1 (en) * | 1993-01-11 | 1995-02-09 | Ligand Pharmaceuticals Inc. | Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors |
| US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
| CZ288526B6 (cs) * | 1994-08-10 | 2001-07-11 | F. Hoffmann-La Roche Ag | Deriváty tetrahydronaftalenu nebo indanu, farmaceutické přípravky na jejich bázi a meziprodukty pro přípravu těchto derivátů |
| IL116259A (en) * | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
| US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
| US5543534A (en) * | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| JP2002515025A (ja) * | 1995-10-06 | 2002-05-21 | リガンド・ファーマシューティカルズ・インコーポレイテッド | ダイマー選択的ｒｘｒモジュレーターおよびその使用方法 |
| US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
| MXPA01009027A (es) * | 1999-03-08 | 2002-08-30 | Basilea Pharmaceutica Ag | Antagonistas de retinoide y uso de los mismos. |
-
1998
- 1998-10-01 US US09/164,950 patent/US6147224A/en not_active Expired - Fee Related
-
1999
- 1999-09-20 WO PCT/US1999/021712 patent/WO2000020370A1/en not_active Ceased
- 1999-09-20 DE DE69912973T patent/DE69912973T2/de not_active Expired - Fee Related
- 1999-09-20 ES ES99970078T patent/ES2207339T3/es not_active Expired - Lifetime
- 1999-09-20 AU AU60513/99A patent/AU757932B2/en not_active Ceased
- 1999-09-20 NZ NZ510528A patent/NZ510528A/xx unknown
- 1999-09-20 KR KR1020017004018A patent/KR20010075457A/ko not_active Abandoned
- 1999-09-20 JP JP2000574489A patent/JP2002526516A/ja active Pending
- 1999-09-20 EP EP03025774A patent/EP1388534A3/en not_active Withdrawn
- 1999-09-20 CN CN99813787A patent/CN1328538A/zh active Pending
- 1999-09-20 CA CA002346034A patent/CA2346034A1/en not_active Abandoned
- 1999-09-20 BR BR9914256-2A patent/BR9914256A/pt not_active Application Discontinuation
- 1999-09-20 AT AT99970078T patent/ATE254593T1/de not_active IP Right Cessation
- 1999-09-20 EP EP99970078A patent/EP1117628B1/en not_active Expired - Lifetime
- 1999-10-01 AR ARP990104996A patent/AR020691A1/es not_active Application Discontinuation
- 1999-10-12 TW TW088116960A patent/TW580494B/zh not_active IP Right Cessation
-
2001
- 2001-03-30 ZA ZA200102635A patent/ZA200102635B/en unknown
-
2006
- 2006-09-20 KR KR1020060091029A patent/KR20060118367A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU757932B2 (en) | 2003-03-13 |
| DE69912973D1 (de) | 2003-12-24 |
| KR20010075457A (ko) | 2001-08-09 |
| EP1388534A2 (en) | 2004-02-11 |
| US6147224A (en) | 2000-11-14 |
| DE69912973T2 (de) | 2004-07-22 |
| CN1328538A (zh) | 2001-12-26 |
| TW580494B (en) | 2004-03-21 |
| HK1039477A1 (en) | 2002-04-26 |
| EP1117628A1 (en) | 2001-07-25 |
| CA2346034A1 (en) | 2000-04-13 |
| ATE254593T1 (de) | 2003-12-15 |
| ES2207339T3 (es) | 2004-05-16 |
| KR20060118367A (ko) | 2006-11-23 |
| AU6051399A (en) | 2000-04-26 |
| JP2002526516A (ja) | 2002-08-20 |
| AR020691A1 (es) | 2002-05-22 |
| EP1117628B1 (en) | 2003-11-19 |
| ZA200102635B (en) | 2002-10-18 |
| WO2000020370A1 (en) | 2000-04-13 |
| BR9914256A (pt) | 2001-07-03 |
| EP1388534A3 (en) | 2004-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ510528A (en) | 2, 4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | |
| NL300396I1 (nl) | Nieuwe derivaten met naftalinestructuren, werkwijze voor de bereiding ervan en de farmaceutische preparaten die deze bevatten | |
| HUP0401819A2 (hu) | Proteinkináz inhibitorokként alkalmazható pirazolvegyületek és ezeket tartalmazó gyógyszerkészítmények | |
| IT1251144B (it) | Derivati del benzimidazolone | |
| FR2369263A1 (fr) | Nouveaux derives de la piperidine | |
| HRP20010514B1 (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
| FI951614A0 (fi) | D-vitamiinisarjan 25-karboksyylihappojohdannaisia, menetelmät niiden valmistamiseksi, näissä menetelmissä käytettävät välituotteet, näitä johdansia sisältävät farmaseuttiset valmisteet ja näiden johdannaisten käyttö lääkeaineiden valmistukseen | |
| AR019190A1 (es) | Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos | |
| KR890005035A (ko) | 벤조일아미노페녹시부탄산 유도체와 그의 제조방법 및 이를 포함하는 제약조성물 | |
| GB1301224A (enExample) | ||
| SE0201658D0 (sv) | Immediate release pharmaceutical formulation | |
| ATE487690T1 (de) | 2-aminobicyclo 3.1.0 hexan-2,6- dicarbonsäureesterderivat | |
| AR039495A1 (es) | Derivados del acido dihidrobenzofurano o dihidrobenzotiofen 2,4-pentadienoico con actividad selectiva sobre receptores retinoides x (rxr) | |
| ATE115558T1 (de) | Harnstoffderivate, deren herstellung sowie diese enthaltende pharmazeutische zusammensetzungen. | |
| GB1530074A (en) | Rho-acetamidophenol derivatives the preparation thereof and the use of such derivatives as therapeutic agents | |
| GB1415471A (en) | Phenylethylamine derivatives | |
| EP1390343A4 (en) | NOVEL RETINOID DERIVATIVES, METHODS FOR PREPARING THESE COMPOUNDS, AND ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| ATE265451T1 (de) | 2-aminoidan derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| MA26921A1 (fr) | Derives d'acides aminés cycliques utilisables en tant qu'agents pharmaceutiques. | |
| GB1479684A (en) | Process for the preparation of aromatic aldehydes | |
| GB1474907A (en) | Pyrolidine derivatives | |
| IE39658L (en) | N-substituted glycinate pharmaceuticals | |
| ATE251177T1 (de) | Bizyklische amino-pyrazinon-derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen die diese enthalten | |
| AR041026A1 (es) | Derivados de aril- y heteroarilmorfolina, su uso en la preparacion de un medicamento y composicion farmaceutica | |
| GB1460811A (en) | Bis-benzamido-benzoic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ALLERGAN, INC., US Free format text: OLD OWNER(S): ALLERGAN SALES, INC. |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |